Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress
January 29, 2025 08:45 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on...
Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland
January 27, 2025 06:00 ET
|
Greenwich LifeSciences, Inc.
STAFFORD, Texas, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01
January 23, 2025 06:00 ET
|
Greenwich LifeSciences, Inc.
STAFFORD, Texas, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
Hepion Pharmaceuticals Announces $9.0 Million Public Offering
January 22, 2025 08:00 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic...
Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
January 08, 2025 09:50 ET
|
Biofrontera Inc.
Last patient completed 1 year follow-up of study ALA-BCC-CT013 in December 2024.Data from follow-up will be included in FDA submission, expected in Q3 2025.Biofrontera announced highly statistically...
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 03, 2025 17:20 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market
December 23, 2024 09:30 ET
|
Biofrontera Inc.
Biofrontera started commercial distribution of the RhodoLED XL in June 2024 and has seen rapid uptake in the US market since launch.The RhodoLED XL is approved by the FDA in combination with Ameluz®...
Aridis Provides Corporate Update
December 20, 2024 08:00 ET
|
Aridis Pharmaceuticals, Inc.
LOS GATOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today announced a corporate update on recent...
Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board
December 17, 2024 08:30 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules
December 13, 2024 16:05 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...